We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


  Gold Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Tryptophan Metabolism Is Dysregulated in Individuals with Fanconi Anemia

By LabMedica International staff writers
Posted on 20 Jan 2021
Print article
Image: Tryptophan metabolism is dysregulated in individuals with Fanconi anemia (Photo courtesy of Cincinnati Children’s Hospital Medical Center).
Image: Tryptophan metabolism is dysregulated in individuals with Fanconi anemia (Photo courtesy of Cincinnati Children’s Hospital Medical Center).
Fanconi anemia (FA) is a complex genetic disorder frequently associated with progressive marrow failure and a strong predisposition to early malignancies, particularly squamous cell carcinomas and hepatocellular carcinomas.

Tryptophan is an essential amino acid necessary for protein synthesis. Tryptophan metabolism has been closely linked to alterations in the microbiome, and dysregulation of the tryptophan pathway has significant implications for host immune regulation, gut inflammation, and overall health.

Hematologists at the Cincinnati Children’s Hospital Medical Center (Cincinnati, OH, USA) and their associates collected blood and stool samples from 23 patients with FA (52% females and age range 5-27 years) and 29 patients with other diagnoses (31% females and age range 1-18). The team studied tryptophan metabolism in FA by examining tryptophan and its metabolites before and during the stress of hematopoietic stem cell transplant (HSCT). Tryptophan can be converted to serotonin and kynurenine.

Plasma levels of tryptophan and metabolites were measured by using an enzyme-linked immunosorbent assay (ELISA): tryptophan (Abnova, Taipei, Taiwan); serotonin and melatonin (Enzo, Farmingdale, NY, USA); kynurenine (BlueGene Biotech, Shanghai, China); transforming growth factor β1 (TGF-β1, R&D Systems, Minneapolis, MN, USA).

Total RNA was isolated from peripheral blood mononuclear cells (PBMCs) and the expression of indoleamine 2,3-dioxygenase, tryptophan hydroxylase 1, and serotonin transporter were measured by RT-qPCR on an Applied Biosystems 7300 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). The team also performed immunochemistry using a Olympus BX53 microscope (Olympus America, Waltham, MA, USA). Nuclear magnetic resonance was also carried out on the plasma samples.

The scientists reported that that serotonin levels are markedly elevated 14 days after HSCT in individuals with FA, in contrast to individuals without FA. Kynurenine levels are significantly reduced in individuals with FA compared with individuals without FA, before and after HSCT. Most peripheral serotonin is made in the bowel. However, serotonin levels in stool decreased in individuals with FA after transplant, similar to individuals without FA. Instead, the team detected serotonin production in the skin in individuals with FA, whereas none was seen in individuals without FA.

Serotonin and TGF-β levels were closely correlated with platelet count before and after HSCT in persons without FA. In FA, neither baseline serotonin nor TGF-β correlated with baseline platelet count (host-derived platelets), only TGF-β correlated 14 days after transplant (blood bank-derived platelets).

The authors concluded that their findings suggest that serotonin inhibition as a new avenue to diminish a multitude of clinical risks and disease phenotypes in FA, which will now require detailed characterization of local and systemic serotonin metabolism. The study was published on January 7, 2021 in the journal Blood Advances.

Related Links:
Cincinnati Children’s Hospital Medical Center
BlueGene Biotech
Thermo Fisher Scientific
Olympus America
R&D Systems

Gold Supplier
Tumor Marker Control
Tumor Marker Control
Saliva Collection Kit
Saliva Collection Kit
Silver Supplier
Remote Lab Review Software
CellaVision Remote Review Software
D-Dimer ELISA Kit
D-Dimer AccuBind ELISA Kit

Print article
BIOHIT  Healthcare OY



view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.